Medobar, known generically as Dobasic Hydrazide Tablets, treats Parkinson’s disease, symptomatic Parkinson’s syndrome, but not drug-induced Parkinson’s syndrome.
Medobar, known as Dobasic Hydrazide Tablets, is a combination of levodopa and benserazide, which is one of the most commonly used medications for the treatment of Parkinson’s disease.
Patients with Parkinson’s disease mainly suffer from symptoms caused by insufficient levels of dopamine in the basal ganglia of the brain, and Dobasic Hydrazide Tablets increase dopamine levels by supplementing dopamine biosynthesis precursor (levodopa), thus improving symptoms.
Benserazide is a peripheral dopa decarboxylase inhibitor and acts similarly to carbidopa. Dobasic hydrazide tablets are made as a combination of levodopa and benserazide in a proportional ratio.
The drug is contraindicated in hypersensitivity to its components, in patients under 25 years of age, as well as in pregnant and lactating women, and its use in combination with non-selective monoamine oxidase inhibitors is prohibited.
The drug should be taken under the guidance of a professional physician and strictly in accordance with medical advice, and it is forbidden to blindly use the drug on its own, so as not to cause adverse consequences.